

PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Dala Alari	440 B' - de - c' de -	Role of DNA Methylation in Liquid-liquid Phase
Bah, Alaji	110 Biochemistry	Separation-mediated Heterochromatin Formation
Pak Alaii	110 Biochomistry	A new phase in ABI1 biology: AR We AbI to
Bah, Alaji	110 Biochemistry	characterize the inractable AR-DNA-ABI1 axis?
Bah, Alaji	110 Biochemistry	Investigating the mechanism of Ess1-mediated
Sun, Aluji	TTO BIOCHERINSTRY	regulation of the CTD of RNAP II phase separation
Chen, Xin Jie	110 Biochemistry	Pathways reversing protein import clogging on the mitochondrial surface
		iviecnanism of mitochondria induced proteostatic
Chen, Xin Jie	110 Biochemistry	signaling and progressive muscle atrophy during
Chan Vin Iin	110 Disaba mista	A novel mitochondrial to lysosome stress signaling
Chen, Xin Jie	110 Biochemistry	pathway in degenerative disease and aging
Chen, Xin Jie	110 Biochemistry	Role of adaptation to mitochondria mediated
Cheff, Alli Tie	110 biochemistry	proteostatic stress in heart function
Chen, Xin Jie	110 Biochemistry	Novel mechanism of neural and muscular
	,	degeneration
Chen, Xin Jie	110 Biochemistry	Role of mitochondrial proteostatic signaling in
·	,	neurodegeneration
Chen, Xin Jie	110 Biochemistry	Mechanism of Mitochondria-induced Progressive
		Muscle Wasting Mechanism of mitochondria induced proteostatic
Chen, Xin Jie	110 Biochemistry	signaling and progressive muscle atrophy during
	,	aging
Chen, Xin Jie	110 Biochemistry	Mechanism of mitochondria induced myokine
Cherry Amore	TTO DIGGRETHISELY	activation and implications for healthy aging
Cosgrove, Michael	110 Biochemistry	Molecular mechanisms for the assembly and
	,	regulation of the MLL1 core complex
Feng, Wenyi	110 Biochemistry	Understanding the genome maintenance function of
		the Fragile X Protein (FMRP)
Feng, Wenyi	110 Biochemistry	Genome maintenance functions of FMRP
		A redesigning existing drugs against indispensable
Hanes, Steven D	110 Biochemistry	targets (ReEDIT) platform technology for discovery
		of novel drugs to treat fungal infections
Kane-Popp, Patricia M	110 Biochemistry	Regulation and cellular functionsof V-ATPases
Knutson, Bruce A.	110 Biochemistry	New paradigms for the molecular basis of RNA
Midt3011, Bruce A.	110 biochemistry	polymerase I transcription
		Directed evolution approach to investigate the
Knutson, Bruce A.	110 Biochemistry	structure based DNA binding mechanism of RNA
		polymerase I core factor
Loh, Dr. Stewart N	110 Biochemistry	Molecular devices for the detection of and
		treatment of HCMV infection
Loh, Dr. Stewart N	110 Biochemistry	Development of modular synthetic sensors for protein biomarke detection
		Combining protein and DNA engineering to create
Loh, Dr. Stewart N	110 Biochemistry	bioswitches
Loh, Dr. Stewart N	110 Biochemistry	Mechanism and detection of LECT2 amyloidosis
Ridilla, Jessica L.	110 Biochemistry	Mechanisms of coordinated actin and microtubule
mama, ressica E.	110 blockeringery	dynamics
Wilkens, Dr. Stephan	110 Biochemistry	Regulation of the human vaculoar H+-ATPase by
-7	,	TLDc domain proteins
Wilkens, Dr. Stephan	110 Biochemistry	Structure and regulatory mechanisms of the
1	,	vacuolar ATPase



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Bowen, Elizabeth	110 Bioethics	Professional Education for anti-ableist health care
Brown, Amy E.	110 Bioethics	Sysematically redressing bias and integrating health equity into medical education: A multimedia web-based toolkit
		limid hisaan of salitan mandalan itah
Wan, Dr. Yuan	020 Biomedical Engineering	Liquid biopsy of solitary pulmonary nodule with extracellular vesicles
		I
Amack, Jeffrey	110 Cell & Developmental Biology	Four dimensional prediciton and quantification of how physical forces impace organogenesis in zebrafish
Bechler, Marie E.	110 Cell & Developmental Biology	Mechanotransduction control of CNS myelin sheat lenght
Krendel, Mira F	110 Cell & Developmental Biology	Design of the Glomerulus and bOwman cApsuLe or a chip (GOAL)
Krendel, Mira F	110 Cell & Developmental Biology	Role of myosin 1e in podocyte biology and renal filtration
Krendel, Mira F	110 Cell & Developmental Biology	Class I myssins regulate protruusive forces at the actin-membrane interface
Krendel, Mira F	110 Cell & Developmental Biology	Assay development for analysis of the motor activity of class I myosins
Pruyne, David W.	110 Cell & Developmental Biology	FRET-based probes for measuring force distribution in living muscle
Turner, Dr. Christopher E	110 Cell & Developmental Biology	Structure and function of paxillin
Wang, Jushuo	110 Cell & Developmental Biology	Support for the analysis of off target effects on cardiac muscle by doxorubicin used to treat breast cancer
Wang, Jushuo	110 Cell & Developmental Biology	Analyses of off target effects on cardiac muscle by inhibitors of the UPS and non-UPS designed to treamultiple myeloma
Mu, Dr. Xiuqian	030 Department of Ophthalmology	Regulation of mRNA decay in retinal development and maintenance
Brenner, Jay M	110 Emergency Medicine	Disco thermometer engineering study
Heyboer, Marvin	110 Emergency Medicine	Hyperbaric oxygen therapy for ulcerative colitis patients hospitalized for moderate to severe flare:
Paolo, William F.	110 Emergency Medicine	1/2 ICECAP: Influence of cooling duration on efficac in cardiac arrest patients trial
Brangman, Dr. Sharon A	110 Geriatrics	A phase 2A-B randomized double blind placebo controlled trial to evaluate the efficacy and safety of varoglutamstat in patients with early alzheime disease with a stage gate to phase 2B
Brangman, Dr. Sharon A	110 Geriatrics	Phase II randomized controlled trial of benfotiamir in early Alzheimer's disease
Brangman, Dr. Sharon A	110 Geriatrics	Alzheimer's network for treatment and diagnostic



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Brangman, Dr. Sharon A	110 Geriatrics	A randomized double blind placebo controlled dose ranging multicenter study of buntanetap in participants with mild to moderate Alzheime's disease
Brangman, Dr. Sharon A	110 Geriatrics	A phase 2 randomized double blind placebo controlled multicenter study to evaluate the efficacy and safety of AL002 in participants with early Alzheimer's disease
Brangman, Dr. Sharon A	110 Geriatrics	Improving adult immunization rates for COVID-19, influenza, and routing adult vaccinations through partnerships with medical subspecialty professional societies and the long term care professional soc
Brangman, Dr. Sharon A	110 Geriatrics	Metformin in Alzheimer's dementia prevention (MAP)
Brangman, Dr. Sharon A	110 Geriatrics	Long term nicotine treatment of mild cognitive impairment
Brangman, Dr. Sharon A	110 Geriatrics	A randomized double blind placebo controlled clinical trila investigating the effect and safety of oral semaglutide in subjects with early Alzheimer's disease (EVOKE plus)
Brangman, Dr. Sharon A	110 Geriatrics	A phase 2A randomized double blind placebo controlled trial to evaluate the efficacy and safety of varoglutamstat in patients with early alzheimers disease with a stage gate to phase 2B
Brangman, Dr. Sharon A	110 Geriatrics	Assessment of safety tolerability and efficacy of donanemab in early symptomatic alzheimer's
Brangman, Dr. Sharon A	110 Geriatrics	A Multicenter, Long-Term, Extension Study to Evaluate the Safety, Tolerability, and Efficacy of AL002 in Participants with Alzheimer's Disease
Brangman, Dr. Sharon A	110 Geriatrics	Early identification of cognitive impairment: A central NY pilot
Varghese, Dona	110 Geriatrics	Improving adult immunization rates for COVID-19, influenza, and routine adult vaccinations through partnerships with medical subspecialty
Basnet, Alina	110 Medicine	A phase III randomized open label multicenter study to determine the efficacy and safety of durvalumab in combination with tremelimumab and enfortumab vedotin or durvalumab in combination with enfortumab vedotin for
Basnet, Alina	110 Medicine	A Phase 3 Study of Androgen Annihilation in High- Risk Biochemically Relapsed Prostate Cancer
Basnet, Alina	110 Medicine	A Phase 2, Randomized, Open-Label, Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer(Protocol CP-MGD019-02)
Benjamin, Sam	110 Medicine	EMBER-4: a randomized opend label phase 3 study of adjuvant imlunestrant vs standard adjuvant endocrine therapy
Benjamin, Sam	110 Medicine	A dose escalaion and expansion study of the safety and efficacy of XL092 in combination with immuno-oncology agents in subject with unresectable advanced or metastatic solid tumors



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Benjamin, Sam	110 Medicine	MammaPrint, BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiless: An Adaptable Registry (FLEX Registry)
Benjamin, Sam	110 Medicine	A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilmumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of
Benjamin, Sam	110 Medicine	PALLAS: PALbocicib Collaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)/human epidermal.
Benjamin, Sam	110 Medicine	Randomized open label phase 3 study of adjuvant sacituzumab govitecan and pembrolizumab vs treatment of physician's choice in patients with triple negative breast cancer
Bhargava, Ramya	110 Medicine	A phase 2 randomized double blind placebo controlled dose finding study to evaluate the efficacy and safety of ALXN2050 in adult participants with proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN)
Chaudhuri, Debanik	110 Medicine	IMPact on revascularization outcomes of intravascular ultrasound guided treatment of complex lesions and economic impact (IMPROVE)
Dvorak, Andrea M	110 Medicine	Retrospective experience assessing the real world utilization and effectiveness of SEVENFACT in the USA
Dvorak, Andrea M	110 Medicine	Public health surveillance for bleeding disorders
Geier, Christian	110 Medicine	Potential pathogenic functins of HLA-DR positive myeloid subsets in rheumatoid arthritis
Gentile, Teresa C	110 Medicine	A phase II multicenter open label single arm dose escalation study of Asciminib monotherapy in 2nd and 1st line chronic phase
Gentile, Teresa C	110 Medicine	A single arm open label pharmacokinetic safety and efficacy study of ASTX727 in combinations with venetoclax in adult patient with acute myeloid leukemia
Gentile, Teresa C	110 Medicine	A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma
Ghimire, Krishna B	110 Medicine	A phase 3 randomized study comparing talquetamab SC in combination with daratumumab SC and pomalidomide or talquetamab
Ghimire, Krishna B	110 Medicine	Open label phase 2 single arm study of selinexor, daratumumab, carfilzomib, and dexamethasone for high risk relapsed and elapsed/refratory multiple myeloma patients who have received 1-3 prior lines of therapy



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
		A phase II study of lenalidomide, ixazomib,
Ghimire, Krishna B	110 Medicine	dexamethazone, and daratumumab in transplant
		ineligible patients with newly diagnosed multiple myeloma
		A Phase II Study of CPX-351 in Younger Patients <
Ghimire, Krishna B	110 Medicine	60 Years Old with Secondary Acute Myeloid
		Leukemia (Protocol No. I-501719)
		A Phase 3 Kandomized Study Comparing Talquetamab in Combination with Pomalidomide
Ghimire, Krishna B	110 Medicine	(Tal-P), Teclistamab (Tal-Tec), and Inverstigator's
G		Choice in Participants with Relapsed or Refractory
		Myoloma
		A post authorization safety study to evaluate the
Ghimire, Krishna B	110 Medicine	incidence of and risk factors for severe and fatal infusion related reactions in participants treated
		with daratumumab
		Transcriptomic predictors and biomarkers of sepsis
Ghosh, Auyon J	110 Medicine	induced cariomyopathy
Chash America	110 Madisina	Genetic and transcriptomic resilience in chronic
Ghosh, Auyon J	110 Medicine	obstructive pulmonary disease
Gilligan, Diana M	110 Medicine	Public Health Surveillance for the prevention of
Gilligan, Diana W	TTO Wedidite	complications of bleeding disorders
Gilligan, Diana M	110 Medicine	Von Willebrand Disease Minimize Menorrhagia
		(VWDMin) Trial CASCADE LUNG: Cancer screening assay using
Graziano, Dr. Stephen L	110 Medicine	DELFI: a clinical validation study in lung (DELFI-
		A randomized phase 3 study of MRTX849 versus
Graziano, Dr. Stephen L	110 Medicine	Docetaxel in patients with previously treated non
		small cell lung cancer with KRAS G12C mutation
		CHIO3 Trial: Chemotherapy Combined with Immune
Graziano, Dr. Stephen L	110 Medicine	Checkpoint Inhibitor for Operable stage IIIA Non-
		Small Cell Lung Cancer Efficacy and Safety of Tirzepatide Once Weekly vs
		Placebo for the Treatment of Obesity and Weight-
Hansen, David	110 Medicine	Related Comorbidities in Adolescents: A
	TIO WEGICHE	Randomized, Double-Blind, Placebo-Controlled Trial
		(SURMOUNT-ADOLESCENTS-2)
		A randomized double blind placebo controlled
		active comparator multicenter study to evaluate
Harausz, Elizabeth P.	110 Medicine	the efficacy and safety of an amikacin liposome
		inhalation suspension based regimen in adult
		subject with newly diagnosed nontuberculous
Holz, George G	110 Medicine	Second generation GLP-1 agonists without
		nausea/emesis side effects
Holz, George G	110 Medicine	Alpha 7 nicotinic acetylcholine receptor regulation of glucagon like peptide 1 incretin hormone action
Izquierdo, Roberto E		A multicenter randomized double blind crossover
	110 Medicine	phase 2 study evaluating the saety and efficacy of hormone replacement therapy with ST-1891
	110 Medicine	compared to Levothyroxine in patient with primary
		hypothryroidism
		A prospective study to evaluate maternal and fetal
Joshi, Sumendra	110 Medicine	outcomes in the ERa of modulatorS
Vechl Mr. Stophen I	110 Modicino	Learning to talk (treat all like kin) & education
Knohl, Mr. Stephen J	110 Medicine	through theater arts



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Meyer, Jenny A.	110 Medicine	A Phase 2B/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by an Open-Label Extension in Subjects with ALS (COMBAT-ALS)
Mix, Michael D	110 Medicine	A pivotal randomized open label study of Optune (ttfields, 200KHZ) concomitany with radiation therapy and temozolomide for the treatment of newly diagnosed glioblastoma
Murthy, Dr. Uma K	110 Medicine	A phase 3 multi center multi national randomized double blind placebo controlled induction and maintenance study to evaluate the efficacy and safety of CC-93538 in adult and adolescent subjects with eosinophilic esophagitis
Murthy, Dr. Uma K	110 Medicine	Open label extension study to evaluate the long term safety of CC-93538 in adult and adolescent subjects with eosinophilic esophagitis
Paolino, Mr. Kristopher	110 Medicine	A phase 3 randomized placebo controlled observer blinded trial to evaluate the safety of 6-valend ospa based lyme disease vaccine (VLA15) in healthy children 5 through 17 years of age
Paolino, Mr. Kristopher	110 Medicine	A phase 3, multicenter, placebocontrolled, randomized, observer-blinded trial to evaluate the efficacy, safety, tolerability,
Paolino, Mr. Kristopher	110 Medicine	A phase 2 randomized double blind placebo controlled study for the prophylactic examination of an antiviral in a dengue challenge model
Paolino, Mr. Kristopher	110 Medicine	Controlled study of immunogenicity and safety of the investigational vYE Candidate Vaccine in comparison to YF-VAX in adults
Paolino, Mr. Kristopher	110 Medicine	A phase 2b multicenter randomized open-label assessor blinded superiority study to compare the efficacy and safety of dalbavancin to standard of care antibiotic therapy for the completion of treatment of patients with
Paolino, Mr. Kristopher	110 Medicine	A low interventional ethodology study to obtain biological samples from participants with suspected lyme disease for the purpose of developing clincial diagnostic assays
Paolino, Mr. Kristopher	110 Medicine	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Adult Patients Receiving Standard of Care Antibiotics for the Treatment of Staphylococcus aureus Bloodstream Infections
Paolino, Mr. Kristopher	110 Medicine	A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-Co\ 2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID-19
Paolino, Mr. Kristopher	110 Medicine	LIAISON LymeDetect and tick borne diseases trial
Paolino, Mr. Kristopher	110 Medicine	Tick Bite: evaluating exposure to ticks by measuring antibody in humans targeting tick saliva in a prospective cohort



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
		A phase III randomized double blind placebo
Perl, Dr. Andras	110 Medicine	controlled multicenter study to evaluate the
		efficacy of safety of obinutuzumab
		Multicenter randomized double blind
David Da Andrea	110 Mar di nima	placebocontrolled phase 2 study evaluating the
Perl, Dr. Andras	110 Medicine	efficacy and safety of daxdilimab in adult
		participants with active proliferative lupus
Darl Dr. Andres	110 Modicino	Rab4A control of liver dysfunction in mouse models
Perl, Dr. Andras	110 Medicine	of systemic lupus erythematosus
		A phase 1b multicenter open label dose escalation
		study to evaluate the safety tolerability
Perl, Dr. Andras	110 Medicine	pharmacokinetics and pharmacodynamics of
		subcutaneously administered mosunetuzumab to
		participants with systemic lupus erythematosus
		A multicenter randomized double blind placebo
		controlled parallel group two arm phase 2 clincial
Perl, Dr. Andras	110 Medicine	trial to evaluate the efficacy and safety of
		LY3361237 to treat adults with at least moderately
		active systemic lupus erythematosus
Perl, Dr. Andras	110 Medicine	Rab4A control of liver dysfunction in mouse models
Peri, Dr. Afluras	TTO Medicine	of systemic lupus erythematosus
		A multicenter randomized double blind placebo
		controlled phase 3 study to evaluate the efficacy
Perl, Dr. Andras	110 Medicine	and safty of B11B059 in adult participants with
		active systemic lupus erythematosus receiving
		background nonbiologic lupus standare of care
		A two year phase III randomized double blind
		paralled group placebo controlled trial to evaluate
Perl, Dr. Andras	110 Medicine	the safety, efficacy, and tolerability of 300 mg s.c.
		secukinumab versus placebo in combination with
		SoC therapy inpatients with active lupus n
		A phse 2b dose ranging study to evaluate the
		efficacy and safety of Efavaleukin Alfa in subjects
Perl, Dr. Andras	110 Medicine	with active systemic lupus erythematosus with
		inadequate response to standard of care therapy
		A multi-center randomized double-blind placebo
		controlled paralled group study to evaluate the
Perl, Dr. Andras	110 Medicine	efficacy and safety of dapirolizumab pegol in study
,	The tweeterne	participants with moderately to severly active
		systemic lupus erythematosus
		A Phase 3, Double-Blind, Multicenter Study to
		Evaluate the Long-Term Safety and Efficacy of
Perl, Dr. Andras	110 Medicine	Baricitinib in Patients with Systemic Lupus
		Erythematosus (SLE)
		A Phase z pose ranging study to Evaluate the
		Efficacy and Safety of AMG 570 in Subjects With
Perl, Dr. Andras	110 Medicine	Active Systemic Lupus Erythematosus (SLE) With
		Inadequate Response to Standard of Care (SOC)
		Thoron
Perl, Dr. Andras	110 Medicine	Metabolic control of systemic autoimmunity
		A Phase 2B, Double-Blind, Randomized, Placebo-
		Controlled, Multicenter, Dose-Ranging Study to
Perl, Dr. Andras	110 Medicine	Evaluate the Efficacy and Safety Profile of PF-
		06700841in Participants with Active Systemic Lups



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Perl, Dr. Andras	110 Medicine	Lupus, Autoimmunity, Inflammatin and Immune
		Health Center of Excellence (LACE)
Poiesz, Dr. Bernard J	110 Medicine	A study of ABC008 in subjects with t-cell large
		granular lymphocytic leukemia
		A phase 3 open label randomized study of fixed duration pirtobrutinib (LOXO-305) PLUS
Poiesz, Dr. Bernard J	110 Medicine	VENETOCIAS AND RITUXIMAB VS VENETOCIAX &
rolesz, Dr. Bernard J	Tio Wedicine	RITUXIMAB IN PREVIOUSLY TREATED CHRONIC
		LYMPHOCYTIC LEUKEMIA
Poiesz, Dr. Bernard J	110 Medicine	Research in Leukemia & related blood disorders
. 5.652, 2.1. 26.11.4.4	Table Tabl	CADENCE registry cold agglutinin disease real work
Poiesz, Dr. Bernard J	110 Medicine	evidence registry
		A Phase 3 Multicenter, Double-Blind, Randomized,
		Placebo-Controlled Study of the Efficacy, Safety,
Poiesz, Dr. Bernard J	110 Medicine	and Tolerability of Rozanolixizumab in Adult Study
		Participants with Persistent or Chronic Primary
		Immune Thrombocytopenia (ITP)
		Open-label, Phase 1b/2 Study of Acalabrutinib
Poiesz, Dr. Bernard J	110 Medicine	Alone or in Combination with Rituximab in Subjects
		with Indolent B-cell Non-Hodgkin Lymphoma
		A Phase 3, Multicenter, Randomized, Double-Blind,
		Placebo-Controlled, Parallel-Group Study of the
Poiesz, Dr. Bernard J	110 Medicine	Efficacy and Safety of Lenalidomide (Revlimid) as
		Maintenance Therapy for Patients with B-Cell
		Chronic Lymphocytic Leukemia Following Second-L
		A Phase 3 Randomized, Open-Label, Multicenter
		Study of Zanubrutinib (BGB-3111) Plus Anti-CD20
Poiesz, Dr. Bernard J	110 Medicine	Antibodies Versus Lenalidomide Plus Rituximab in
		Patients With Relapsed/Refractory Follicular or
	<u> </u>	Marginal Zone Lymphoma
		A phase 2 multicenter randomized double blind
Reddy, Elizabeth A.	110 Medicine	placebo controlled study to evaluate efficacy, safety, tolerability and pharmacokinetics of
		Budigalimab and/or ABBV-382
Reddy, Elizabeth A.	110 Medicine	People Aging with HIV Pilot Project A restropective survey analysis of Pre-exposure
Reddy, Elizabeth A.	110 Medicine	prophyklaxis (PrEP) in HIV positive individuals in
	220	CNIV
		A prospective and retrospective observational
Reddy, Elizabeth A.	110 Medicine	study of multidrug resistant patient outcomes with
	120 Mediane	and without ibalizumab in a real world setting:
		United States
		A Phase IIIb, Randomized, Multicenter, Active-
5 11 51 1 1 4		controlled, Parallel-group, Non-inferiority, Open-
Reddy, Elizabeth A.	110 Medicine	label Study Evaluating the Efficacy, Safety, and
		Tolerability of Switching to Long-acting
		Cabotegravir Plus Long-acting Rilpivirine
		A Phase III, randomized, multicentre, parallel-
Reddy Flizabeth A	110 Medicine	group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravis
Reddy, Elizabeth A.	110 Medicine	plus lamivudine in HIV-1 infected adults who are
		virologically suppressed
Dedd Elisted A	440 NA . II	
Reddy, Elizabeth A.	110 Medicine	People Aging with HIV



Reddy, Elizabeth A. 110 Medicine Advancing health equity through comprhensive community based HIV ambulatory care services A phase 3 multicenter randomized open label active controlled study of sotorasib and panturummab vs investigators choice (trifluridine it practice) and the previously treated metastic colorectal cancer (INITIUM: A randomized phase II open label active controlled multicenter study investigating the efficacy and safety of UV accination in combination with involumab and iplimurnab as fire line treatment of patients with unresectable of metastic colorectal cancer INITIUM: A randomized phase II open label active controlled multicenter study investigating the efficacy and safety of UV accination in combination with involumab and iplimurnab as fire line treatment of patients with unresectable of metastic colorectal cancer A Phase 3, Randomized, Double-Blind Study of Parmevulumab or Placebo in combination with Gentlabine Plus Nab-paditaxel or FOLFIRINOX as Neadywant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer SERENA-4: A randomized multicenter double blind phase III study of A209833 (an Oral SERD) plus palbodicity anastrozole plus palbodiciti for the treatment of patients with locally Advanced, Unresectable Pancreatic Cancer SERENA-4: A randomized multicenter double blind phase III study of A209833 (an Oral SERD) plus palbodiciti for the treatment of patients with estgrogen receptor-positive HER2 negative advanced breast cancer we have a patient of patients with estgrogen receptor-positive HER2 negative advanced breast cancer we have a patient of patients with estgrogen receptor-positive HER2 negative advanced breast cancer we have a patient of patients with estgrogen receptor-positive HER2 negative advanced breast cancer we have a patient of patients with estgrogen receptor-positive HER2 negative advanced breast cancer we have a patient of patients with estgrogen receptor-positive HER2 negative advanced breast cancer we have a patient of the patients of t	The Office of Research for Medical Students PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
community based HIV ambulatory care services A phase 3 multicenter randomized open label active controlled study of sotorasib and panitumumab vs investigators choice (trifluid) and tiprical, or regorafenib) for the treatment of previously treated metastic colorectal cancer INTITUM: A randomized phase III open label active controlled multicenter study investigating the efficacy and safety of UV1 vaccination in combination with involumab and ipilimumab as fine treatment of previously treated metastic colorectal cancer INTITUM: A randomized phase III open label active controlled multicenter study investigating the efficacy and safety of UV1 vaccination in combination with involumab and ipilimumab as fine treatment of patients with unresectable of me SESPOKE study of ctDNA guided therapy in colorectal cancer A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with color part of the part			
A phase 3 multicenter randomized open label active controlled study of sotorasib and panitumumab vs investigators choice (trifluridine tipiradi, or regorafenib) for the treatment of previously treated metastic colorectal cancer INTIUM: A randomized phase II open label active controlled multicenter study investigating the efficacy and safety of UV1 vaccination in combination with involumab and pilinumumab as fir line treatment of patients with unresectable of me BESPOKE study of cDNA guided therapy in colorectal cancer 10 Medicine BESPOKE study of cDNA guided therapy in colorectal cancer 110 Medicine BESPOKE study of cDNA guided therapy in colorectal cancer 12 A Phase 3, Randomized, Double-Blind Study of Parmevlumab or Placebo in combination with Generitabine Plus Aba-pacitized or FOLFIRINOX as Neoadjuvant Treatment in Patients with locally Advanced, Unresectable Pancreatic Cancer 12 SERENA-4: A randomized multitentre double blind phase III study of AZD9833 (an Oral SERD) plus sisvapiragasam, Abirami 110 Medicine Bloodidus ora sanstrozole plus palbocidib for the treatment of patients with estgrogen receptor-positive HER2 negative advanced breast cancer appears of the pase 3 clinical Trial of Pembrolaba plus diff. 347 in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Aphase 2 randomized observer-blinds fundy to evaluate the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase Istudy of the safety tolerability and immunogenicity of GLS-5310 DNA vaccine against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase Istudy of the safety tolerability and immunogenicity of GLS-5310 DNA vaccine against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase Istudy of the safety tolerability and immunogenicity of GLS-5310 DNA vaccine against COVID-19 when administered after prior receipt of adenovirus based COVID-19 P	Reddy, Elizabeth A.	110 Medicine	
seth, Rahul 110 Medicine Seth, Rahul 110 Medicine 110 Medi			
ieth, Rahul 110 Medicine panitumumab vs investigators choice (trifluridine it tipiracil, or regorafenib) for the treatment of previously treated metastic colorectal cancer INITIUM: A randomized phase II open label active controlled multicenter study investigating the efficacy and safety of UV1 vacination in combination with nivolumab and ipilimumab as fir line treatment of patients with unresectable of me seth, Rahul 110 Medicine BESPOKE study of ctDNA guided therapy in colorectal cancer A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with seth, Rahul 110 Medicine Gemitabine Plus Nab-paditaxel or FOLFiRINOX as Neoadjuvant Treatment in Plus Placebo in combination with Quintersectable Pancreatic Cancer SERENA-4: A randomized multicentre double blind phase III study of AZD9833 (and roral SERD) plus palbocicili by anastrozole plus palbocidib for the treatment of patients with setgrogen receptor-positive HERZ negative advanced breast cancer A Phase 3 Clinical Trial of Pembrolizumab (MK-347 in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous CEI Carcinoma A phase 2 randomized observer-blind study to evaluate the safety tolerability and immunogenicity of SARS-CoV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of SARS-CoV-2RNA vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe the fifthmas, Stephen J. 110 Medicine Innovation centers (CIVIC): design and execution Option 13A.1 A Phase I/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe the fifthmas, Stephen J. 110 Medicine Safety, Tolerability, Immunogenicity of Ose-Note A Phase III Double blind Radnomised Placebo contrile Study of adjuvant Osimetricinib			i .
tipiradi, or regorafenib) for the treatment of previously treated metastic colorectal cancer and an armonized phase lope label active controlled multicenter study investigating the efficacy and safety of UV1 vaccination in combination with nivioumab and pillimumab as fir line treatment of patients with unresectable of metastic colorectal cancer. June 110 Medicine SESPOKE study of ctDNA guided therapy in colorectal cancer. A Phase 3, Randomized, Double-Blind Study of Parmevlumab or Placebo in combination with Gernal treatment of patients with Locally Advanced, Unresectable Pancreatic Cancer. Seth, Rahul 110 Medicine Gernal treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer. SERENAL4: A randomized multicentre double blind phase III study of AZD9833 (an Oral SERD) plus palbodicib was nastrozole plus palbodicib for the treatment of patients with estgregen receptor-positive HER2 negative advanced breast cancer was plus particents of the patients with estgregen receptor-positive HER2 negative advanced breast cancer was plus plandicib for the treatment of Patients with estgregen receptor-positive HER2 negative advanced breast cancer was plus plandicib for the treatment of Patients with estgregen receptor-positive HER2 negative advanced breast cancer was plus plus plus plus plus plus plus plu			
previously treated metastic colorectal cancer INITIUM: A randomized phase II open label active controlled multicenter study investigating the seth, Rahul 110 Medicine Seth, Rahul Seth, Seth	Seth, Rahul	110 Medicine	i - · · · · · · · · · · · · · · · · · ·
INITIUM: A randomized phase II open label active controlled multicenter study investigating the efficacy and safety of UV1 vaccination in combination with nivolumab and ipillmumab as fir line treatment of patients with unresectable of me BESPOKE study of ctDNA guided therapy in colorectal cancer A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Cooling and Placebo Controlled, Advanced, Unresectable on in combination with Locally Advanced, Unresectable poin combination with Locally Advanced, Unresectable point combination with Locally Advanced, Unresectable processing and patients with Locally Advanced, Unresectable processing and patients with Locally Advanced, Unresectable patients with Locally Advanced place and Local Patients with Locally Advanced place and Local Patients with Locally Advanced place and Local Patients with Locally Blind phase III study of AZD9833 (an Oral SERO) plus palbocidib for the treatment of Patients with estgrogen receptor-positive HER2 negative advanced breast cancer with Locally Advanced Local Loc			, , , , , , , , , , , , , , , , , , , ,
controlled multicenter study investigating the efficacy and safety of UV1 vaccination in combination with nivolumba and ipilimumab as fine treatment of patients with unresectable of me into the patients with unresectable of patients with unresectable of patients with unresectable of patients with study of AD981 and patients with locally advanced, Unresectable Pancreatic Cancer SERENA-4: A randomized multicentre double blind phase III study of AD9833 (an Oral SERO) plus palbocidib va anastrozole plus palbocidib for the treatment of patients with estgrogen receptor-positive HER2 negative advanced breast cancer we applicate the patients with estgrogen receptor-positive HER2 negative advanced breast cancer we applicate the patients with estgrogen receptor-positive HER2 negative advanced breast cancer we applicate the patients with estgrogen receptor-positive HER2 negative advanced breast cancer we applicate the safety tolerability and immunogenicity of SARS-COV-2 and vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 when administered after prior receipt of adenovirus based COVID-19 when administered after prior receipt of adenovirus based COVID-19 when administered after prior receipt of adenovirus based COVID-19 when administered after prior receipt of adenovirus based COVID-19 when administered after prior receipt of adenovirus based COVID-19 when administered after prior receipt of adenovirus based COVID-19 when administered after prior receipt of adenovirus based COVID-19 when administered after prior receipt of adenovirus based COVID-19 when administered after prior receipt of adenovirus based covidation and immunogenicity of GLS-5310 DNA vaccine against COVID-19 when a			
seth, Rahul 110 Medicine efficacy and safety of UV1 vaccination in combination with nivolumab and injimimmab as fir line treatment of patients with unresectable of me BESPOKE study of ctDNA guided therapy in colorectal cancer A Phase 3, Randomized, Double-Blind Study of Parmevlumab or Placebo in combination with Gemitabine Plus Nab-pacitizate or FOLFIRINOX as Neoadjuvant Treatment planeties with Locally Advanced, Unresectable Pancreatic Cancer SERENA-4: A randomized multicentre double blind phase III study of AZD9833 (an Oral SERD) plus palbocicilib va anastrozole plus palbocidilib for the treatment of patients with estgrogen receptor-positive HER2 negative advanced breast cancer w A Phase 3 Clinical Trial of Pembrolizumab (MK-347 in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Cardinoma A phase 2 randomized object and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 (Phase I study of the safety tolerability and immunogenicity of SARS-COV-2 (Clinical concenter SCIVIC): design and execution Option 13A.1 A Phase 17,2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA vaccine candidates Against COVID-19 (Homas, Stephen J.) 110 Medicine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 17,2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA vaccine candidates Against COVID-19 (Habita) and immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA vaccine candidates Against COVID-19 (Habita) and Phase III Double blind Randomised Placebo contrile study of adjuvant Osimertinib			· · ·
combination with nivolumab and ipilimumab as fir. line treatment of patients with unresectable of me BESPOKE study of ctDNA guided therapy in colorectal cancer A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-pacilitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer SERENA 4: A randomized multicentre double blind phase III study of AZD9833 (an Oral SERD) plus palbodicib vs anastrozole plus palbodicib for the treatment of patients with estgrogen receptor positive HER2 negative advanced breast cancer we have a palbodicible of the treatment of patients with estgrogen receptor positive HER2 negative advanced breast cancer we have a palbodicible of the treatment of patients with estgrogen receptor positive HER2 negative advanced breast cancer we have a palbodicible of the treatment of patients with estgrogen receptor positive HER2 negative advanced breast cancer we have a palbodicible of the treatment of patients with estgrogen receptor positive HER2 negative advanced breast cancer we have a palbodicible of the treatment of patients with estgrogen receptor positive HER2 negative advanced breast cancer we have a palbodicible of the treatment of patients with estgrogen receptor positive HER2 negative advanced breast cancer we have a palbodicible of the treatment of patients of the receptor positive HER2 negative advanced breast cancer we have a palbodicible of the receptor positive HER2 negative advanced breast cancer we have a palbodicible of the receptor positive HER2 negative advanced breast cancer we have a palbodicible of the receptor positive HER2 negative advanced breast cancer we have a palbodicible of the receptor positive HER2 negative advanced breast cancer with the ad	Soth Pahul	110 Modicino	
BESPOKE study of ctDNA guided therapy in colorectal cancer A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemitabine Plus Nab-paclitaxed or FOLFIRINOX as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer SERENA 4: A randomized multicentre double blind phase III study of AZD9833 (an Oral SERD) plus palbocidib vs anastrozole plus palbocidib for the treatment of patients with estgrogen receptor-positive HER2 negative advanced breast cancer w A Phase 3 Clinical Trial of Pembrolizumab (MK-347 in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma A phase 2 randomized observer-blind study to evaluate the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of GSARS-COV-2RNA vaccine against SARS-COV-2 Clinical core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A. 1 A Phase 17, Placebo Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA vaccine Candidates Against COVID-19 Rhasel II D Medicine Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA vaccine Candidates Against COVID-19 Rhasel II D Medicine Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA vaccine Candidates Against COVID-19 Rhasel II D Double blind Radnomised Placebo controlled, Randomized Oxplorior 15A. I D Medicine Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA vaccine Candidates Against COVID-19 In Healthy Adults Phase III D Double blind Radnomised Placebo controlled, Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA vaccine Candidates Against COVID-19 In Healthy Adults Safety, Tolerability, Immunogenicity, and Potentia Ef	Setti, Ratiui	TIO Medicine	
BESPOKE study of ctDNA guided therapy in colorectal cancer A Phase 3, Randomized, Double-Blind Study of Parmevlumab or Placebo in combination with Gemitabine Plus Nab-pacitizate or FOLFIRINOX as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer SERENA-4: A randomized multicentre double blind phase III study of AZD9833 (an Oral SERD) plus silvapiragasam, Abirami 110 Medicine			·
colorectal cancer A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Geth, Rahul 110 Medicine Gemcitabine Plus Nab-pacitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer SERENA-4: A randomized multicentre double blind phase III study of AZD9833 (an Oral SERD) plus palbocidib vs anastrozole plus palbocidib vs anastrozole plus palbocidib vs anastrozole plus palbocidib vs the treatment of patients with estgregen receptor-positive HER2 negative advanced breast cancer where the safety advanced breast cancer where the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of GLS-5310 DNA vaccine against COVID-19 when administered after prior receipt of adenovirus based COVID-19 when administered after prior receipt of adenovirus based COVID-19 when administered innovation centers (CIVIC): design and execution Option 13A.1 A Phase I Study of the safety tolerability, and immunogenicity of GLS-5310 DNA vaccine against SARS-COV-2 Clincial core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase I J.2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentic Efficacy of SARS-COV-2 RNA Vaccine candidates Against COVID-19 in Healthy Adults A 2 part multicenter dose titration study of oxybutynin chloride Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib			
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gentiabine Plus Nab-paditaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer SERNA-4: A randomized multicentre double blind phase III study of AZD9833 (an Oral SERD) plus palbocicilib vs anastrozole plus palbocidib for the treatment of patients with estgrogen receptor-positive HER2 negative advanced breast cancer w A Phase 3 Clinical Trial of Pembrolizumab (MK-347 in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma A phase 2 randomized observer-blind study to evaluate the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 hase I study of the safety tolerability and immunogenicity of GIS-5310 DNA vaccine against SARS-COV-2 Clinical core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults A 2 part multicenter dose titration study of oxybutynin chloride Wallen, Jason M.	Seth, Rahul	110 Medicine	
Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paditaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer SERENA-4: A randomized multicentre double blind phase III Study of AZD9833 (an Oral SERD) plus palbocidib vs anastrozole plus palbocidib for the treatment of patients with estgrogen receptor-positive HER2 negative advanced breast cancer w A Phase 3 Clinical Trial of Pembrolizumab (MK-347 in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma A phase 2 randomized observer-blind study to evaluate the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of GIS-5310 DNA vaccine against SARS-COV-2 Clinical core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults A Pase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib			
Seth, Rahul 110 Medicine Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer SERENA-4: A randomized multicentre double blind phase III study of AZD9833 (an Oral SERD) plus palbociclib vs anastrozole plus palbociclib for the treatment of patients with estgrogen receptor-positive HER2 negative advanced breast cancer w A Phase 3 Clinical Trial of Pembrolizumab (MK-347 in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma A phase 2 randomized observer-blind study to evaluate the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-COV-2 Clinical core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults A 2 part multicenter dose titration study of oxybutynin chloride Wallen, Jason M. 110 Medicine Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib			· · · · · · · · · · · · · · · · · · ·
Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer SERENA-4: A randomized multicentre double blind phase III study of AZD9833 (an Oral SERD) plus palbocicibi vs anastrozole plus palbocicibi for the treatment of patients with estgrogen receptor-positive HER2 negative advanced breast cancer was palbocial trial of Pembrolizumab (MK-347 in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma A phase 2 clinical Trial of Pembrolizumab (MK-347 in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma A phase 2 randomized observer-blind study to evaluate the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2. Clinical core for collaborative influenza vaccine innovation centres (CIVIC): design and execution Option 13A.1. A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults A 2 part multicenter dose titration study of oxybutynin chloride Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib	Seth. Rahul	110 Medicine	
Advanced, Unresectable Pancreatic Cancer SERENA-4: A randomized multicentre double blind phase III study of AZD9833 (an Oral SERD) plus palbocicibl vs nastrozole plus palbocicibl for the treatment of patients with estgrogen receptor-positive HER2 negative advanced breast cancer w A Phase 3 Clinical Trial of Pembrolizumab (MK-347 in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma A phase 2 randomized observer-blind study to evaluate the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of GIS-5310 DNA vaccine against SARS-COV-2 CRIA vaccine against CRIA phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults Villanueva, Jeffrey 110 Medicine A 2 part multicenter dose titration study of oxybutynin chloride Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib	,		· ·
phase III study of AZD9833 (an Oral SERD) plus palbociclib vs anastrozole plus palbociclib for the treatment of patients with estgrogen receptor-positive HER2 negative advanced breast cancer w A Phase 3 Clinical Trial of Pembrolizumab (MK-347. in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma A phase 2 randomized observer-blind study to evaluate the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of GIS-5310 DNA vaccine against SARS-COV-2 Clinical core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults A 2 part multicenter dose titration study of oxybutynin chloride Wallen, Jason M. 110 Medicine Phase III Double blind Radnomised Placebo controlled study of adjuvant Osimertinib			1
110 Medicine palbociclib vs anastrozole plus palbociclib for the treatment of patients with estgrogen receptor-positive HERZ negative advanced breast cancer w A Phase 3 Clinical Trial of Pembrolizumab (MK-347 in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma A phase 2 randomized observer-blind study to evaluate the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase 1 study of the safety tolerability and immunogenicity of GSAS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase 1 study of the safety tolerability and immunogenicity of GS-5310 DNA vaccine against SARS-COV-2 Clinical core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults A/Illanueva, Jeffrey Nallen, Jason M. 110 Medicine Phase III Double blind Radnomised Placebo controlled study of adjuvant Osimertinib			SERENA-4: A randomized multicentre double blind
110 Medicine palbociclib vs anastrozole plus palbociclib for the treatment of patients with estgrogen receptor-positive HERZ negative advanced breast cancer w A Phase 3 Clinical Trial of Pembrolizumab (MK-347 in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma A phase 2 randomized observer-blind study to evaluate the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase 1 study of the safety tolerability and immunogenicity of GSAS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase 1 study of the safety tolerability and immunogenicity of GS-5310 DNA vaccine against SARS-COV-2 Clinical core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults A/Illanueva, Jeffrey Nallen, Jason M. 110 Medicine Phase III Double blind Radnomised Placebo controlled study of adjuvant Osimertinib			phase III study of AZD9833 (an Oral SERD) plus
treatment of patients with estgrogen receptor- positive HER2 negative advanced breast cancer w A Phase 3 Clinical Trial of Pembrolizumab (MK-347 in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma A phase 2 randomized observer-blind study to evaluate the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of GIS-5310 DNA vaccine against SARS-COV-2 Clinical core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults A 2 part multicenter dose titration study of oxybutynin chloride Wallen, Jason M. 110 Medicine Phase III Double blind Radnomised Placebo controlled Study of adjuvant Osimertinib	Sivapiragasam, Abirami	110 Medicine	
A Phase 3 Clinical Trial of Pembrolizumab (MK-347 in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma A phase 2 randomized observer-blind study to evaluate the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-COV-2 Clinical core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults A 2 part multicenter dose titration study of oxybutynin chloride Wallen, Jason M. 110 Medicine Phase III Double blind Radnomised Placebo controlled study of adjuvant Osimertinib			li i i
in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma A phase 2 randomized observer-blind study to evaluate the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2 Clincial core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults A 2 part multicenter dose titration study of oxybutynin chloride Wallen, Jason M. 110 Medicine Phase III Double blind Radnomised Placebo controlled Study of adjuvant Osimertinib			positive HER2 negative advanced breast cancer w
Head and Neck Squamous Cell Carcinoma A phase 2 randomized observer-blind study to evaluate the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-COV-2 Clincial core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults //illanueva, Jeffrey Nallen, Jason M. Head and Neck Squamous Cell Carcinoma A phase 2 randomized observer-blind study of firm munogenicity and immunogenicity of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults A 2 part multicenter dose titration study of oxybutynin chloride Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib			A Phase 3 Clinical Trial of Pembrolizumab (MK-3475)
A phase 2 randomized observer-blind study to evaluate the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-COV-2 Clincial core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults //illanueva, Jeffrey 110 Medicine A 2 part multicenter dose titration study of oxybutynin chloride Phase III Double blind Radnomised Placebo contrille study of adjuvant Osimertinib	Sivapiragasam, Abirami	110 Medicine	in First Line Treatment of Recurrent/Metastatic
evaluate the safety tolerability and immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-COV-2 Clincial core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults //illanueva, Jeffrey Nallen, Jason M. 110 Medicine Phase III Double blind Radnomised Placebo controlled study of adjuvant Osimertinib			Head and Neck Squamous Cell Carcinoma
Thomas, Stephen J. 110 Medicine immunogenicity of SARS-COV-2RNA vaccine candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-COV-2 Clincial core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults //illanueva, Jeffrey Nallen, Jason M. 110 Medicine immunogenicity of SARS-COV-2 NNA Vaccine Candidates Against COVID-19 in Healthy Adults A 2 part multicenter dose titration study of oxybutynin chloride Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib			A phase 2 randomized observer-blind study to
candidates against COVID-19 when administered after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2 Clincial core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults //illanueva, Jeffrey 110 Medicine 110 Medicine Phase III Double blind Radnomised Placebo controlled study of adjuvant Osimertinib			evaluate the safety tolerability and
after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2 Clincial core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults //illanueva, Jeffrey 110 Medicine after prior receipt of adenovirus based COVID-19 Phase I study of the safety tolerability and immunogenicity and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults //illanueva, Jeffrey 110 Medicine Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib	Thomas, Stephen J.	110 Medicine	immunogenicity of SARS-COV-2RNA vaccine
Phase I study of the safety tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2 Clincial core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults //illanueva, Jeffrey Nallen, Jason M. 110 Medicine Phase III Double blind Radnomised Placebo controlled in munogenicity and potential possible in the study of adjuvant Osimertinib			candidates against COVID-19 when administered
Thomas, Stephen J. 110 Medicine immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2 Clincial core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults //illanueva, Jeffrey 110 Medicine 110 Medicine Phase III Double blind Radnomised Placebo controlled study of adjuvant Osimertinib			
SARS-CoV-2 Clincial core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults //illanueva, Jeffrey 110 Medicine A 2 part multicenter dose titration study of oxybutynin chloride Wallen, Jason M. 110 Medicine Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib			
Clincial core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults //illanueva, Jeffrey 110 Medicine A 2 part multicenter dose titration study of oxybutynin chloride Wallen, Jason M. 110 Medicine Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib	Thomas, Stephen J.	110 Medicine	
Thomas, Stephen J. 110 Medicine innovation centers (CIVIC): design and execution Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults //illanueva, Jeffrey 110 Medicine 110 Medicine Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib			
Option 13A.1 A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults //illanueva, Jeffrey 110 Medicine Nallen, Jason M. 110 Medicine Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib	Thomas Stanban I	110 Modicino	
A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults //illanueva, Jeffrey 110 Medicine Nallen, Jason M. 110 Medicine A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe the Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults A 2 part multicenter dose titration study of oxybutynin chloride Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib	Thomas, Stephen 1.	TTO Medicine	
Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults //Illanueva, Jeffrey 110 Medicine Nallen, Jason M. 110 Medicine Observer-Blind, Dose-Finding Study to Describe th Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults A 2 part multicenter dose titration study of oxybutynin chloride Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib		<u> </u>	-
Thomas, Stephen J. 110 Medicine Safety, Tolerability, Immunogenicity, and Potentia Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults A 2 part multicenter dose titration study of oxybutynin chloride Wallen, Jason M. 110 Medicine Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib			
Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults /illanueva, Jeffrey 110 Medicine A 2 part multicenter dose titration study of oxybutynin chloride Wallen, Jason M. 110 Medicine Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib	Thomas, Stephen J.	110 Medicine	
Against COVID-19 in Healthy Adults A 2 part multicenter dose titration study of oxybutynin chloride Wallen, Jason M. 110 Medicine Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib	Thomas, ecephicins		
/illanueva, Jeffrey 110 Medicine A 2 part multicenter dose titration study of oxybutynin chloride Wallen, Jason M. 110 Medicine Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib			· ·
Wallen, Jason M. 110 Medicine oxybutynin chloride Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib			-
Wallen, Jason M. Phase III Double blind Radnomised Placebo contrile study of adjuvant Osimertinib	Villanueva, Jeffrey	110 Medicine	
study of adjuvant Osimertinib	Mallan Jacon M	110 Markinina	Phase III Double blind Radnomised Placebo contrlled
	vvalieri, Jason IVI.	110 Medicine	study of adjuvant Osimertinib
Automated insulin delivery in elderly (AIDE): a			Automated insulin delivery in elderly (AIDE): a
Weinstock Dr. Ruth S 110 Modising randomized cross over trial evaluation automated	Weinstock, Dr. Ruth S	110 Medicine	randomized cross over trial evaluation automated
insulin delivery technologies on hypoglycemia and	Wellistock, Dr. Ruth 3	110 Medicine	insulin delivery technologies on hypoglycemia and
quality of life in elderly adults with type 1 diabete			quality of life in elderly adults with type 1 diabete
Open single arm propective multicenter study of a			Open single arm propective multicenter study of an
Neinstock, Dr. Ruth S 110 Medicine investigational extended wear insulin infusion set	Weinstock, Dr. Ruth S	110 Medicine	investigational extended wear insulin infusion set
during home use in people with type 1 diabetes			during home use in people with type 1 diabetes



DEPARTMENT/DIVISION	PROJECT TITLE
110 Medicine	INHALE-3 A 17 week randomized trial and a 13 week extension evaluating the efficacy and safety of Afrezza combined with Degludec (Tresiba) versus usual care in adults with Type 1 diabetes
110 Medicine	A randomized trial evaluating the efficacy and safety of control-IQ technology in adults with type 2 diabetes using basal bolus insulin therapy
110 Medicine	A phase 2 randomized placebo controlled double blind dose ranging study to evaluate the efficacy safety and tolerbility oa AMG 133 in adult subjects with overweight or obesity with or without type 2 diabetes mellitus
110 Medicine	A phase 3 multicenter randomized paralled design open label study to evaluate the efficacy and safet of LY3209590 as a weekly basal insulin compared with insulin deludec in participants with type 1 diabetes treated with multiple daily inje
110 Medicine	T1D Exchange QI Collaborative Adult
110 Medicine	Evaluating the safety and effectiveness of the Omnipod 5 System compared to pump therapy in the treatment of type 1 diabetes: a randomized parallel group clinical trial
110 Medicine	An integrated care model for older adults with insulin treated diabetes
110 Medicine	A Brief Telehealth Intervention to Address Diabetes Health-Related Quality of Life (HRQOL) in Families of Youth
110 Medicine	Evaluating the Safety and Effectiveness of the Omnipod Horizon Automated Glucose Control System in Patients with Type 1 Diabetes
110 Medicine	Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes
110 Medicine	comparing HDV-insulin lispro versus insulin lispro alone in adults with Type 1 Diabetes receiving
110 Microbiology	Evaluation of the safety and efficacy of a virus like particle vaccine for prevention of Chikungunya virus disease
110 Microbiology	Defining correlates of protection from dengue illness in a long term cohort study of multigenerational house-holds in Thailand
110 Microbiology	Targeting nuclear HSF1 as a novel anti-HCMV strategy
110 Microbiology	Mechanisms of HCMV-induced monocyte-to- macrophage differentiation
110 Microbiology	Development of an attenuation strategy for West Nile Virus
110 Microbiology	SHIP1 agonism and lipid burden in Alzheimer's
<u> </u>	disease
	110 Medicine 110 Microbiology 110 Microbiology 110 Microbiology 110 Microbiology



The Office of Research for Medical Students PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TILE
Koenig, Andreas	110 Microbiology	Collaborative research: scaling of neutrophil
		functins in terrestrial mammals
Koenig, Iwona A.	110 Microbiology	Ribosomal skipping under oxidative stress in SLE
Moffat, Dr. Jennifer F	110 Microbiology	Xenograft mouse models for varicella zoster virus and human sytomegalovirus
Moffat, Dr. Jennifer F	110 Microbiology	Murine cutaneous model for herpes simplex virus antiviral research
		VZV vaccine attenuation and the DNA damage
Moffat, Dr. Jennifer F	110 Microbiology	response
Murphy, Eain A.	110 Microbiology	Alzheimer's disease associated pathology induced by neurotropic viral infection
Murahu Fain A	110 Microbiology	Antiviral responses of host mediatd S-nitrosylation
Murphy, Eain A.	110 Microbiology	of viral proteins
Pruyne, David W.	110 Microbiology	FHOD proteins in striated muscle cytoskeletal organization
Day Mathaga	110 Missabialass	Manipulating CrkL signaling to increase T cell
Roy, Nathan	110 Microbiology	function in breast cancer
Roy, Nathan	110 Microbiology	Defining casL as an orchestrator of T cell migration
Spring, Michele	110 Microbiology	Role of primaquine pharmacokinetics in treatment efficacy for vivax malaria
Taylor, Harry E.	110 Microbiology	Center for structural biology of HIV RNA
Thangamani, Saravanan	110 Microbiology	Tick Surveillance
Thangamani, Saravanan	110 Microbiology	Tick Study
Thangamani, Saravanan	110 Microbiology	Development of a Lyme Vaccine
		A phase 3 randomized observer blinded study to
Thomas, Stephen J.	110 Microbiology	evaluate the safety tolerability and immunogenicity of a combined RNA vaccine
		An open label multi center enabling study to
Thomas, Stephen J.	110 Microbiology	evaluate influenza like illnesses and severe
		influenza disease in adults aged 65 years and abov
		High definition immunologic profiling following
Thomas, Stephen J.	110 Microbiology	open label adminisration of a tetravaletn dengue
	TIO WICE OBIOLOGY	vaccine to people in Thailand with different
		baseline flavivirus immuni status
		A phase 1/2 randomized dose finding/dose confirmation study to evaluate the reactogenicity
Thomas, Stephen J.	110 Microbiology	safety and immunogenicity of mRNA based
Thomas, stephens.	Tio Wild obliding,	multivalent seasonal influenza vaccine candidates
		administered in healthy younger and older adults
		A phase I placebo controlled randomized observer
		blind dose finding study to evaluate the safety
Thomas, Stephen J.	110 Microbiology	tolerability and immunogenicity of self amplifying
		RNA vaccine preparations against influenza in
		healthy individuals
Thomas, Stephen J.	110 Microbiology	Human Challenge: AT-452 in Dengue
		A phase I double blind randomized placebo
Thomas Stophon I	110 Microbiology	controlled study to assess the antiviral activity and
Thomas, Stephen J.	110 Microbiology	safety of AT-752 in a Dengue human challenge
		model
		Exploring dose and schedule variations of a novel
Thomas, Stephen J.	110 Microbiology	dengue antiviral prophylaxis intervention to
		support US military operational requirements



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
		A phase 1/2/3 randomized study to evaluate the
Thomas, Stephen J.	110 Microbiology	safety tolerability and immunogenicity of a
monas, scephens.	TIO WICH OSIGIOS Y	modified RNA vaccine against influenza in healthy
		A phase 3 lot to lot consistency study to evaluate
Thomas, Stephen J.	110 Microbiology	V181 in healthy adults 18 to 30 years of age
Thomas, Stephen J.	110 Microbiology	COVID surveillance cohort
Majekman Adam T	110 Microbiology	Scientific support for viral diseases branch (VDB)
Waickman, Adam T.	110 Microbiology	research projects
Waickman, Adam T.	110 Microbiology	Landscape analysis for prevention of dengue
·	<u> </u>	infection
Waickman, Adam T.	110 Microbiology	Assessing the in vitro anti-dengue virus activity of
		Assessing the impact of seasonal coronavirus
Waickman, Adam T.	110 Microbiology	crossreactivity on the durability and diversity of
,		SARS-CoV-2 speficia cellular immunity
		Assessment of dengue virus (DENV) reactive IgA
Waickman, Adam T.	110 Microbiology	expressing plasmablasta as an early biomarker of
walckman, Adam 1.	110 Microbiology	dengue severity and antagonist of DENV-elicited
		inflammation
Waickman, Adam T.	110 Microbiology	Long term durability of DENV specific immunity
	,	after vaccinatin in a dengue endemic population
Waickman, Adam T.	110 Microbiology	Custom designed IgA monoclonal antibodies for
		treating flavivirus infection
Wilmore, Joel R.	110 Microbiology	Defining the role of T-bet in systemic IgA
Wilmore, Joel R.	110 Microbiology	Mechanisms of commensal bacteria induced
		humoral immunity
		A first in human (FIH) study of inhibitory
Beach, Dr. Robert L	110 Neurology	interneurons (NRTX-1001) in drug resistant
		unilateral mesial temporal lob epilepsy (MTLE) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
		CONTROLLED, PARALLEL GROUP, MULTICENTER
Beach, Dr. Robert L	110 Neurology	TRIAL OF CVL-865 AS ADJUNCTIVE THERAPY IN
•		ADULTS WITH DRUG-RESISTANT FOCAL ONSET
		SEIZURES (REALIZE TRIAL)
		An Open-Label, Multicenter, Extension Study to
Beach, Dr. Robert L	110 Nourology	Evaluate the Safety and Efficacy of Padsevonil as
Beach, Dr. Robert L	110 Neurology	Adjunctive Treatment of Focal-Onset Seizures in
		Adult Subjects with Drug-Resistant Epilepsy
		A phase 3 randomized double blind placebo
Bradshaw, Dr. Deborah Y	110 Neurology	controlled paralled multicenter study to evaluate
	120 11001 01087	the safety and efficacy fo ALXN1720 in adults with
		generalized myasthenia gravis A phase 3 open label extension of COURAGE-ALS (0
Bradshaw, Dr. Deborah Y	110 Neurology	5031)
		CY 5031: A phase 3 multi center double blind
		randomized placebo controlled trial to evaluate th
Bradshaw, Dr. Deborah Y	110 Neurology	efficacy and safety of Reldesemtiv in patients with
Bradshaw, Dr. Deborah Y		chicacy and safety of heraesement in patrents with
Bradshaw, Dr. Deborah Y		amyotrophic lateral sclerosis (ALS)
Bradshaw, Dr. Deborah Y Burke, Devin	110 Neurology	



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Chabrashvili, Tinatin	110 Neurology	A randomized double blind placebo controlled parallel group study to assess the efficacy safety and tolerability of BBIIB080 in subjects with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia
Izadyar, Shahram	110 Neurology	Randomized, Double-blind, Placebo-Controlled, Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Adults Diagnosed With Epilepsy
Izadyar, Shahram	110 Neurology	A rendomized double blind placebo controlled multicenter phase 3 study to evaluate the saety tolerability and efficacy of XEN1101 as adjunctive therapy in primary generalized tonic clonic seizures
Izadyar, Shahram	110 Neurology	A randomized double blind placebo controlled multicenter phase 3 study to evaluate the safety tolerability and efficacy of XEN1101 as adjunctive therapy in focal onset seizures
lzadyar, Shahram	110 Neurology	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy
Langan, Dr. Thomas J J	030 Neurology	Enhancement of Newborn Screening Diagnostic Paradigms to Improve the Efficacy of Treatment for Krabbe Disease, Pompe Disease, and Mucopolysaccharidosis Type 1
Latorre, Dr. Julius Gene S.	110 Neurology	REpeated AS seSsmEnt of SurvivorS in ICH (REASSESS ICH)
Latorre, Dr. Julius Gene S.	110 Neurology	A multicenter adaptive randomized controlled platform trial of the safety and efficacy of antithrombotic strategies in hospitalized adults with COVID-19
Latorre, Dr. Julius Gene S.	110 Neurology	Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE)
Latorre, Dr. Julius Gene S.	110 Neurology	Sleep for Stroke Management and Recovery Trial (Sleep SMART) Stroke Trial
Latorre, Dr. Julius Gene S.	110 Neurology	Multi-arm Optimization of Stroke Thrombolysis (MOST) Stroke Trial
Latorre, Dr. Julius Gene S.	110 Neurology	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction
McGraw, Corey A.	110 Neurology	A randomized open label multi center active comparator study to assess the efficacy safety and tolerability of ofatumumab 20mg sc monthly versus continued current therapy in relapsing remitted multipe sclerosis aftre elevation of serum neuf
McGraw, Corey A.	110 Neurology	A phase 111 multicenter randomized double-blind double-dummy parallel-group study to evaluate the efficacy and safety of fenebrutinib compared with ocrelizumab in adult patients with primary progressive multiple sclerosis



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
McGraw, Corey A.	110 Neurology	An Open-Label, Multicenter Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients with Relapsing Multiple Sclerosis Receiving Treatment with
Medrea, Ioana	110 Neurology	Synchronize: real world retrospective review of safety in patients who have been treated with botox for more than on therapeutic indication
Medrea, Ioana	110 Neurology	GORE CARDIOFORM septal occluder migraine clinical study
Mejico, Dr. Luis	110 Neurology	An Open-Label, Multiple-Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine
Meyer, Jenny A.	110 Neurology	A multicenter, prospective, randomized, placebo- controlled, double-blind, parallel-group clinical trial to assess the efficacy and safety of Immune Globulin Intravenous (Human) Flebogamma 5% DIF in patients with Post-Polio Syndrome
Mihaila, Dr. Dragos	110 Neurology	NN110 - A dose selection trial of light therapy for impaired sleep in Parkinson's Disease
Mihaila, Dr. Dragos	110 Neurology	58 week open-label trial of tavapadon in Parkinson's Disease
Mihaila, Dr. Dragos	110 Neurology	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD
Mihaila, Dr. Dragos	110 Neurology	A Phase 3, Double-Blind, Randomized, Placebo- Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 Trial)
Muniz, Carlos F.	110 Neurology	Cardiac safety of anti-seizuer medications
Sakonju, Ai	110 Neurology	A phase 3 multicenter randomized double blind placebo controlled single attack study to evaluate the efficacy safety tolerability and pharmacokinetics of oral ubrogepant in the acute
Sakonju, Ai	110 Neurology	treatement of migraine with or without aura in A multi center open label extension study to evaluate the long term safet and tolerability of oral ubrogepant in the acute treatment of migraine with or without aura in children and adolescents ages 6-17
Schmidt, Elena	110 Neurology	StATins Use in intRacerebral hemorrhage patieNts (SATURN)
Weinstock-Guttman, Dr. Bianca	030 Neurology	Evaluation of Patient-Reported Outcomes Associated with Natalizumab Use in a Real-World Setting
Young, Eufrosina I.	110 Neurology	An expanded access protocol of intravenous trehalose injection 90 mg/mL treatment of patients with Amyotrophic Lateral Sclerosis
Young, Eufrosina I.	110 Neurology	A phase 3b multicenter randomized double blind extension study to evaluate the continued efficacy and safety of roal edaravone administered for an additional period of up to 48 weeks



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Young, Eufrosina I.	110 Neurology	Trehalose S-005
Young, Eufrosina I.	110 Neurology	Pridopidine - Home spirometry and open label extension period
Young, Eufrosina I.	110 Neurology	A phase 3b multicenter randomized double blind study to evaluate efficacy and safety of oral edaravone administered for a period of 48 weeks i subjects with amyotrophic lateral sclerosis
Young, Eufrosina I.	110 Neurology	Home based spirometry through telemedicine in amyotrophic lateral sclerosis
Young, Eufrosina I.	110 Neurology	HEALEY ALS Platform Trial related to Amyotrophic Lateral Sclerosis
Young, Eufrosina I.	110 Neurology	An intermediate size expanded access protocol for amyotrophic lateral sclerosis with pridopidine
Zhou, Xiangping	110 Neurology	Comprehensive Outcomes Registry in Subjects with Epilepsy Treated with Vagus Nerve Stimulation Therapy (CORE-VNS)
Babu, Harish	110 Neurosurgery	A multi center observational study of gamma tile Surgically Targeted Radiation Therapy (STaRT)
Babu, Harish	110 Neurosurgery	Single neuron correlates of emotional stimuli in human prefrontal cortex
Tovar Spinoza, Zulma S	110 Neurosurgery	Laser Ablation of Abnormal Neurological Tissue using Robotic NeuroBlate System (LAANTERN) Prospective Registry
Ts'o, Dr. Daniel Y	110 Neurosurgery	Assessing vascular pathology in diabetic retinopathy using retinal neurovascular imaging
Weickert, Cynthia	110 Neurosurgery	Discovering how inflammation impairs neurogenesis in human brain
Zhao, Li-Ru	110 Neurosurgery	Revealing novel pathogenic and repairing mechanisms of CADASIL disease
Zhao, Li-Ru	110 Neurosurgery	Exploring mechanisms underlying SCF+G-CSF enhanced recovery in chronic TBI
Klingman, Karen J	110 Nursing	The SLEEPR study: SLEep effects on post stroke rehabilitation
Agarwal, Rinki	110 OB/GYN	Establish PDX ovarian cancer models to test novel nanotherapeutics
Cunningham, Dr. Mary J	110 OB/GYN	A randomized double blind placebo controlled multicenter efficacy and safety trial of single cycle tetrodotoxin in the treatment of chemotherapy induced neuropathic pain
Cunningham, Dr. Mary J	110 OB/GYN	A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Cunningham, Dr. Mary J	110 OB/GYN	Gynecologic Oncology Group Clinical Study
Babino, Darwin	110 Ophthalmology	Assessment of murine retinal acuity ex vivo by machine learning of multielectrode array
		recordings



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Bernstein, Audrey M.	110 Ophthalmology	A single dose anti-scarring therapeutic for the cornea
Bernstein, Audrey M.	110 Ophthalmology	Investigating the role of impaired mitochrondrial dynamics in exfoliation glaucoma
Bernstein, Audrey M.	110 Ophthalmology	The ubiquitin pathway in corneal scarring
Bernstein, Audrey M.	110 Ophthalmology	Cellular dysfunction in exfoliation glaucoma
Brunken, Dr. William Joseph	110 Ophthalmology	Breaching the barrier with matrix biology
Brunken, Dr. William Joseph	110 Ophthalmology	Neuronal Regulation of Vascular Development and Maturation in the Retina
Calvert, Dr. Peter D	110 Ophthalmology	Mechanisms of photoreceptor outer segment assembly
Calvert, Dr. Peter D	110 Ophthalmology	Molecular mechanisms of photoreceptor disc morphogenesis
Calvert, Dr. Peter D	110 Ophthalmology	Mechanisms of photoreceptor protein transport and compartmentalization
Ganapathy, Preethi S.	110 Ophthalmology	Optic nerve head cellular interactions in response to mechanical strain and fibrosis
Ganapathy, Preethi S.	110 Opthalmology	Investigating mechanosensation in the glaucomatous optic nerve head
Herberg, Samuel A.	110 Ophthalmology	Role of cellular memory in glaucoma
Herberg, Samuel A.	110 Ophthalmology	The role of glaucomatous trabecular meshwork cues in driving Schlemm's canal cell mechano-
Herberg, Samuel A.	110 Ophthalmology	TM/SC interface on a chip for mechanistic studies coutflow regulation
Knox, Barry E	110 Ophthalmology	Neuropeptide receptors regulating feeding in ticks
Martinez-DeLuna, Reyna I	110 Ophthalmology	The role of extracellular matrix in axon routing
Martinez-DeLuna, Reyna I	110 Ophthalmology	RPB Career Development Award - The role of B2- and y3- containing laminins in the development of intrinsically photosensitive ganglion cells
Solessio, Eduardo C	110 Ophthalmology	Contribution of rod photoresponse inactivation kinetics to visual temporal contrast sensitivity in mesopic light
Spencer, William J.	110 Ophthalmology	Understanding ectosomes in retinal disease
Todd, Levi	110 Ophthalmology	Investigation of the neuroimmune axis in retinal regeneration
Viczian, Ms. Andrea S	110 Ophthalmology	Control of retinal angiogenesis by Tbx3
Viczian, Ms. Andrea S	110 Ophthalmology	The role of Tbx3 in retinal angiogenesis and eye disease
Kellman, Dr. Robert M	110 Otorhinolaryngology	SCREW DEGREDATION USING THE STORZ BIODEGRADABLE PLATING SYSTEM
Suryadevara, Amar C	110 Otolaryngology	The preservation of hearing function during cisplatin therepy using a telodendrimer nanocarrie in a mouse model



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Jamaspishvili, Tamar	110 Pathology	Single-center retrospective clinical study of artificial intelligence (AI)-based protein assessment of three tumor suppressor genes (?triple-TSG?) for improved risk stratification and treatment management of advanced prostate cancer
Jamaspishvili, Tamar	110 Pathology	Studying the prognostic and predictive role of PD_L1 expression on digital pathology images using artificial intelligence in a pan-cancer retrospective patient cohort undergoing immunotherapy
Sperber, Steven	110 Pathology	Monitoring breast cancer patients at risk of relapse
Andrake, Dr. John S	110 Pediatrics	Collect data based on pulse oximetry overuse and underuse patient observations during the bronchiolitis season
Blatt, Dr. Steven D	110 Pediatrics	Syracuse Family Advocacy Program
Botash, Dr. Ann S	110 Pediatrics	Child Abuse Medical Provider
Comito, Melanie A.	110 Pediatrics	A feasibility and randomized phase 2/3 study of the VEFGR2/MET inhibitor cabozantinib
Comito, Melanie A.	110 Pediatrics	Neuroanatomical, cognitive, and family aspects to recovery from a brain tumor
Comito, Melanie A.	110 Pediatrics	A phase 3 randomized study of selumetinib vs carboplatin/vincristine in newly diagnosed or previously untreated neurobibromatosis type 1 associated with low grade glioma
Comito, Melanie A.	110 Pediatrics	A phase 3 randomized study of selumetinib versus carboplatin/vincristine in newly diagnosed or previously untreated neurofibromatosis type i associated low grade glioma
Comito, Melanie A.	110 Pediatrics	A5481092: A phase 2 study to evaluate the safety and pharfmacokinetics of palbociclib (IBRANCE) in combination with irinotecan and temozolomide in pediatric patients with recurrent or refractory solid tumors
Comito, Melanie A.	110 Pediatrics	An open label feasibility study to assess the safety and pharmacokinetics of enasidenib in pediaric patients with relapsed/refractory acute myeloid leukemia R/R-AML with an isocitrate ehydrogenzse 2IDH1 mutation
Comito, Melanie A.	110 Pediatrics	A safety pharmacokinetic and efficacy study of y- Secretase inhibitor nirogacestat(PF-03084014; IND# 146375) in children and adolescents with progressive surgically unresectable Desmoid
Comito, Melanie A.	110 Pediatrics	A phase 3 study of 1311-metaildobenzylguanidine (1311-MIBG) or ALK inhibitor therapy in children with newly diagnosed high risk NBL
Comito, Melanie A.	110 Pediatrics	ACNS1833-A phase 3 randomized non inferiority study of carboplatin and vincristine vs selumetinib in newly diagnosed or previously untreated low grade glioma not associated with BRAFV600E mutations or systemic neurofribromatotis type 1



The Office of Research for Medical Students		
PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Comito, Melanie A.	110 Pediatrics	media physical activity intervention among adolescent and young adult childhood cancer
Comito, Melanie A.	110 Pediatrics	APAL2020SC Pediatric acute leukemia screening trial-developing new therapies for relapsed leukemias
Comito, Melanie A.	110 Pediatrics	ACCL2031-A phase 3 randomized placebo controlled trial evaluationg memantine for neurocognitive protection in children undergoing cranial radiotherapy as part of treatment for primary central nervous system tumorw
Comito, Melanie A.	110 Pediatrics	A phase 2 study of inotuzumab ozogamicin in children and young adults with relapsed or refractory CD22+B-acute lymphoblastic leukemia (B-ALL), CO ID AALL1621/Pfizer no W1221468
Comito, Melanie A.	110 Pediatrics	NCI-COG pediatric MATCH (molecular analysis for therapy choice) Phase 2 subprotocol of palbociclib in patients with tumors harboring activating alterations in cell cycle genes
Comito, Melanie A.	110 Pediatrics	A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab (GO) to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3
Comito, Melanie A.	110 Pediatrics	A safety pharmacokinetic and efficacy study of ay- Secretase inhibitor Nirogaceastat (PF03084014:IND# 146375) in children and adolescents iwth progressive surgically unresectable desmoid tumors
Comito, Melanie A.	110 Pediatrics	A phase III study of 1311 metaiodobenzylguanidine (1311-MIBG) or critzotinib added to intensive therapy for children with newly diagnosed high risk neuroblastoma (NBL)
Comito, Melanie A.	110 Pediatrics	A randomized trial of a mobile health and social media physical activity intervention among adolescent and young adult childhood cancer
Comito, Melanie A.	110 Pediatrics	Pediatric Match (APEC1621SC) PCR - COG Foundation (Molecular Analysis for Therapy Choice) ADVL18P1 - An Open-Label Feasibility Study to
Comito, Melanie A.	110 Pediatrics	Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-
Comito, Melanie A.	110 Pediatrics	A Phase III Randomized, Open label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children w/ lymphoblastic Leukemia
Comito, Melanie A.	110 Pediatrics	Intensified Methotrexate, Nelarabine (Compound 506U78; NCI IND #52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Comito, Melanie A.	110 Pediatrics	LCH-IV: International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
Comito, Melanie A.	110 Pediatrics	"Head Start 4" Newly Diagnosed Children (Less Than 10 Years Old) with Medulloblastoma and Other Central Nervous System Primitive Neuro- Ectodermal Tumors
Comito, Melanie A.	110 Pediatrics	A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Murtant Acute Lymphoblastic Leukemia (ALL)
Comito, Melanie A.	110 Pediatrics	Health Effects after Anthracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Anthracycline-related Cardiomyopathy
Comito, Melanie A.	110 Pediatrics	Health Effects after Anthracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Anthracycline-related Cardiomyopathy
Comito, Melanie A.	110 Pediatrics	COG Protocol Study: ADVL1322; A Phase 2 Trial of Pazopanib NSC#737754, IND#65747 in Children with Refractory Solid Tumors
Comito, Melanie A.	110 Pediatrics	A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine in the Very High Risk Stratum
Comito, Melanie A.	110 Pediatrics	AALL2121, a phase 2 study of SNDX-5613 in combination with chemotherapy
Conners, Gregory P.	110 Pediatrics	Floyd R. Bates, M.D. Memorial Fund for Research in Leukemia and Related Blood Disorders
Craig, Andrew R	110 Pediatrics	Laboratory analyses of relapse following voluntary abstinence
Cunningham, Dr. Mary J	110 Pediatrics	Phase II study of abemaciclib in combination with letrozole in recurrent or metastic endometriod endometrial cancer
Domachowske, Joseph B.	110 Pediatrics	A phase II single blind randomized controlled study to evaluate the immunogenicity and safety of a measles, mumps, rubella, varicella vaccine compared with ProQuad administered in healthy children 4 to 6 years of age
Domachowske, Joseph B.	110 Pediatrics	A phase 3 randomized observer blind placebo controlled study to evaluat tehe fficacy safety and immunogenicity of mRNA-1647 cytomegalovirus vaccint in healthy participants 16 to 40 years of
Domachowske, Joseph B.	110 Pediatrics	EHR surveillance of lower respiratory tract (LTRI) and respiratory syncytial virus (RSV) in infants
Domachowske, Joseph B.	110 Pediatrics	A phase II observer blind randomized controlled study to evaluate the immunogenicity and safety of a varicella vaccine at various potencies compared with Varivax as a first dose administered in healthy children in their second year of life



The Office of Research for Medical Students	105/	
PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Domachowske, Joseph B.	110 Pediatrics	A phase 2 open label uncontrolled single dose study to evaluate the safety and tolerability pharmacokinetics and occurrence of antidrug antibody for Nirsevimab in immunocompromised children less than or equal to 24 months of age
Domachowske, Joseph B.	110 Pediatrics	A phase 1 open-label dose-finding study to evaluate safety tolerability and immunogenicity and phase2/3 placebo controlled observer blinded safety.
Domachowske, Joseph B.	110 Pediatrics	A Phase 1/2, randomized, observer-blind, controlled, multi-center study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals' respiratory syncytial virus (RSV) investigational vaccine based on the RSV viral
Domachowske, Joseph B.	110 Pediatrics	A Phase 2/3 Randomized, Double-blind, Palivizumab controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Childresn (MEDLEY)
Domachowske, Joseph B.	110 Pediatrics	A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants
Dvorak, Andrea M	110 Pediatrics	Real world use of emicizumab in infants and children ages 0-3 years with hemophilia A
Fortner, Christopher N	110 Pediatrics	A phase 3 open label study evaluating the long term safety and efficacy of VX-121 combinatin therapy in subjects with cyctic fibrosis
Fortner, Christopher N	110 Pediatrics	A phase 3 randomized double blind controlled study evaluating the efficacy and safety of VX-121 combination therapy in subjects with cystic fibrosis who are homozygous for F508del, heterozygous for F508del and a gating (f/G) or residual fun
Fortner, Christopher N	110 Pediatrics	A prospective study to evaluate biological and clinical effects of significantly corrected CFTR function in infants and young children
Fortner, Christopher N	110 Pediatrics	A master protocol to test the impact of discontinuing chronic therapies in people with cystic fibrosis on highly effective CFTR modulator therapy (SIMPLIFY)
Fortner, Christopher N	110 Pediatrics	A Phase 3, Open-label Study Evaluating the Long term Safety of VX-445 Combination Therapy in Subjects with Cystic Fibrosis
Hansen, David	110 Pediatrics	A randomized double blind placebo controlled phase 3 study with an open label extension assessing the efficacy safety and pharmacokinetics/pharmacodynamics of tirzepatide in pediatric and adolsecent participants with type 2 diabetes
Hoose, Danielle L	110 Pediatrics	The EASE of ID project: estblishing autism spectrum disorder signs earlier by following high risk infant development



The Office of Research for Medical Students		
PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Shaw, Andrea V.	110 Pediatrics	Expanding community clinical partnership to continue to improve health equity for refugee and immigrant populations in Syracuse
Sima, Dr. Jody L.	110 Pediatrics	Creating a Childhood Cancer Survivors Database
Soultan, Zafer N	110 Pediatrics	CF-GENES: Addressing genetic counseling access disparities for parents of CF newborn
Sullivan, William E	110 Pediatrics	Integrated platform for measuring and reducing symptoms of autism spectrum disorder
Suryadevara, Manika D	110 Pediatrics	Practice based changes to improve adolescent HPV vaccination rates
Suryadevara, Manika D	110 Pediatrics	The impace of positive vaccine attitudes and communications among primary care office staff on practice level pediatric and adolescent vaccine completion rates
Suryadevara, Manika D	110 Pediatrics	A prospective study to characterize vaccine knowledge, attitudes, and practices amond healthcare providers in NYS
Suryadevara, Manika D	110 Pediatrics	A prospective surveillance study to determine the clinical manifestations pathogen co-detection, temporal patterns of, and meteorologic and air quality factors associated with RSV infection amond young children in the middle income tropical
Wali, Prateek D	110 Pediatrics	Detection of Serum Protein Biomarkers to Predict and Monitor Response to Infliximab Using SOMAscan
Weiner, Dr. Leonard B	110 Pediatrics	Newborn screening follow up study of congenital cytomegalovirus infection
Weiner, Dr. Leonard B	110 Pediatrics	An interventional phase 1b randomized double blind sponsore open placebo controlled multi center dose finding study to evaluate safety tolerability and pharmacokinetics of sisunatovir
Weiner, Dr. Leonard B	110 Pediatrics	A phase 2/3 single arm open label study to evaluate the safety pharmacokinetics and efficacy of obeldesivirs
Weiner, Dr. Leonard B	110 Pediatrics	A phase 3 randomized double blind placebo controlled study to evaluate the efficacy and safety of S-217622 in the prevention of symptomatic SAR-CoV-2 infection in household contacts of an individual with symptomatic COVID-19
Weiner, Dr. Leonard B	110 Pediatrics	A phase 2 randomized double blindplacebo controlled study to evaluate the efficacy and safety of GS-5245 for the treatment of COVID-19 in participants with standard risk for developing severe disease
Weiner, Dr. Leonard B	110 Pediatrics	A phase 2 two part study followed by observer blind/randomized (Part2) to evaluate the safety tolerability reactogenicity and effectiveness of mRNA 1273.214 SARS-CoV-2 vaccine in participants aged 12 weeks to <6 months



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Weiner, Dr. Leonard B	110 Pediatrics	An open label phase 3 study to evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for SARS-CoV-2 variants of concern in participantes aged 6 months to < 6 years
Weiner, Dr. Leonard B	110 Pediatrics	Targeted clinical research to address select viral infections
Weiner, Dr. Leonard B	110 Pediatrics	A phase II observer blind randomized controlled study to evaluate the immunogenicity and safety of a varicella vaccine at various potencies compared with Varivax as a first dose administered in healthy children in their second year of life A phase 2/3 interventional safety pnarmacokinetics
Weiner, Dr. Leonard B	110 Pediatrics	and efficacy open label multi center single arm study to investigate orally administered PF-
Weiner, Dr. Leonard B	110 Pediatrics	A phase 2A open label study assessing pharmacokinetics safety tolerability and immunogenicity of single dose subcutaneous or intramuscular anti-spike (S) SARS-COV-2 monoclonal antibodies (casirivamab and imdevimad) in high risk pediatric su
Weiner, Dr. Leonard B	110 Pediatrics	Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC)
Weiner, Dr. Leonard B	110 Pediatrics	A phase 2/3 two part, open label, dose escalation, age de-escalation and randomized observer blind placebo controlled expansion study to evaluate the safety tolerability reactogenicity and effectiveness of mRNA 1273 SARS CoV2 vaccine in hea
Weiner, Dr. Leonard B	110 Pediatrics	A Phase 2/3, Randomized, Observer-Blind, Placebo Controlled, Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS COV 2 Vaccine in Healthy Adolescents 12 to <18 years of age
Weiner, Dr. Leonard B	110 Pediatrics	Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections (East Syracuse Site)
Weiner, Dr. Leonard B	110 Pediatrics	A Phase 3, Randomized, Double-Blind Trial To Evaluate The Safety And Immunogenicity Of A 20- Valent Pneumococcal Conjugate Vaccine In Healthy Infants
Weiner, Dr. Leonard B	110 Pediatrics	A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regiman of V114 in Healthy Infants (PNEU-PED)
Weiner, Dr. Leonard B	110 Pediatrics	A Phase IIIB, Observer-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine when Administered Concomitantly
Weiner, Dr. Leonard B	110 Pediatrics	A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Immongencity of a Multivalent Pneumococcal Conjugate Vaccine Given With, or Separately From, 13-Valent Pneumococcal Vaccine in Healthy Infants



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Weiner, Dr. Leonard B	110 Pediatrics	A Phase 2, Randomized, Double-Blind Trial To Evaluate the Safety, Tolerability and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants
Weiner, Dr. Leonard B	110 Pediatrics	A Phase 3, Randomized, Modified Double-Blind, Active-Contrilled, Parallel-Group, 2-arm Study to Investigate the Safety of a 4-Dose Regimen of a 21- Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers
Weiner, Dr. Leonard B	110 Pediatrics	A Phase 2, Randomized, Double-blind, Multi-dose, Dose Finding Study to Evaluate the Safety, Tolerability and Immunogenicity of AFX3772 Compared with PVCs in Healthy Infants, Protocol Number AFX3772-003 (219651)
Weiner, Dr. Leonard B	110 Pediatrics	Family Focused HIV Health Care for Women
Weiner, Dr. Leonard B	110 Pediatrics	mRNA-1345-P101
·		
Shaw, Palma M	110 Surgery - General	Improving outcomes in vascular disease-aortic dissection
Damron, Timothy A	110 Surgery - Orthopedics	An Evaluating Study of the Device in the Surgical Treatment of Patients Attending the Hospital Through Reviewing the Device Performance Data (CERAMENT/BONE VOID FILLER Device Registry)
Damron, Timothy A	110 Surgery - Orthopedics	Radiotherapy Effects on Normal Bone
Lavelle, Dr. William F.	110 Surgery - Orthopedics	An interventional multi-center investigation of the balancedback total joint replacement
Lavelle, Dr. William F.	110 Surgery - Orthopedics	M6-C artificial cervical disc two level IDE pivotal study
Lavelle, Dr. William F.	110 Surgery - Orthopedics	Trospective data conection study or patients treated with a single level transformaminal lumbar interbody fusion (TLIF) stabilized iwth pedicle
Lavelle, Dr. William F.	110 Surgery - Orthopedics	M6-C Artificial Cervical Disc IDE Post-Approval Study
Lavelle, Dr. William F.	110 Surgery - Orthopedics	Transforaminal Lumbar Interbody Fusion with
Lavelle, Dr. William F.	110 Surgery - Orthopedics	A Prospective, Multicenter, Randomized, Controlled Clinical Investigation of MONTAGE in Adults with Spinal Deformity Undergoing Pedicle Subtraction Osteotomy
Lavelle, Dr. William F.	110 Surgery - Orthopedics	A Multi-center, Patient Outcome Registry for a Hydroxyapatite infused PEEK Interbody Fusion
Lavelle, Dr. William F.	110 Surgery - Orthopedics	Thoracolumba burst fractures (AoSpine A3,A4) in neurologically intact patients; An observational, multicenter cohort study comparing surgical versus non-surgical treatment
Lavelle, Dr. William F.	110 Surgery - Orthopedics	The INFUSE Bone Graft with MASTERGRAFT Strip PLF Dosing IDE Study
Lavelle, Dr. William F.	110 Surgery - Orthopedics	A Concurrently Controlled Study of LimiFlex(TM) Paraspinous Tension Band in the Treatment of Lumbar Degenerative Spondylolisthesis with Spinal Stenosis



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Lavelle, Dr. William F.	110 Surgery - Orthopedics	Prospective, Concurrently Controlled, Multi-Center Study to Evaluate the Safety and Effectiveness of the Spinal Kinetics M6-C Artificial Cervical Disc Compared to Anterior Cervical Discectomy and Fusion (ACDF) for the Treatment of
Oest, Megan E.	110 Surgery - Orthopedics	Reducing Post-Radiotherapy Bone Fragility Through Orchestrated Cell Survival
Ordway, Mr. Nathaniel R	110 Surgery - Orthopedics	Biomechanical evaluation of pelvic fixation methods: an invetsigation of the distal-ventral iliac pathway fixation method compared to existing
Scerpella, Tamara A	110 Surgery - Orthopedics	Bone Densitometry Study
Setter, Kevin J	110 Surgery - Orthopedics	Prospective clinical study analysing outcomes of anatomic shoulder arthroplasty with SMR metal back glenoid and SMR TT metal back glenoid (S-15)
Setter, Kevin J	110 Surgery - Orthopedics	A randomized multi-center prospective safety and efficacy study comparing the outcome of total reverse shoulder arthroplasty with SMR stemless reverse vs SMR reverse shoulder system
Setter, Kevin J	110 Surgery - Orthopedics	A Post-Market, Prospective, Multi-Center, Open- Label, Single Arm Clinical Evaluation of the Integra? Titan? Modular Shoulder System 2.5 for Primary Shoulder Joint Replacement
Setter, Kevin J	110 Surgery - Orthopedics	Retrospective clinical study analyzing outcomes of anatomic shoulder arthroplasty with SMR Metal Back glenoid and SMR TT Metal Back glenoid in series
Setter, Kevin J	110 Surgery - Orthopedics	A Prospective, Single Center, Randomized Stud to Evaluate the Effectiveness of the T-rex (Total Range Exerciser) Compared to Standard Physical Therapy After Arthroscopic Shoulder Surgery for Rotator Cuff Repair
Tallarico, Richard A	110 Surgery - Orthopedics	A multicenter prospective historically controlled pivotal trial comparing the safety and effectivenes of the Synergy Disc to anterior cervical discectomy and fusion in patients with one level symptomatic certical degenerative disc disease
Werner, Frederick W	110 Surgery - Orthopedics	Cadaver Knee Testing
Bourboulia, Dimitra	110 Surgery - Urology	Regulation of the extracellular HSP90 chaperone machinery
Bratslavsky, Gennady	110 Surgery - Urology	A Phase 2/3, Open-label, Baseline-controlled,
Bratslavsky, Gennady	110 Surgery - Urology	A multi center open label randomized phase 3 trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus hormone therapy in patients with metastatic castration resistant prostate cancer
Bratslavsky, Gennady	110 Surgery - Urology	Phase 3 multicenter double blind randomized placebo controlled trial of infigratinib for the adjuvant treatment of subjects with invasive urothelial carcinoma with susceptible FGFR3 genetic alterations
Bratslavsky, Gennady	110 Surgery - Urology	A phase 2b randomized trial of autologous dendriticell immunotherapy



PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Bratslavsky, Gennady	110 Surgery - Urology	Specimen collection in patients with renal cell carcinoma to assess tissue correlates of therapeutics:COSMIC 313 population
Bratslavsky, Gennady	110 Surgery - Urology	A multicenter, Randomized, controlled phase 2 study: Efficacy and safety of I-131-1095 Radiotherapy in combination with enzalutamide in metastatic castration-resistant prOstate cancer (mCRPC) patients Who are F-DCFPyL prostate-
Bratslavsky, Gennady	110 Surgery - Urology	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Apalutamide in Subjects with High risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy
Bratslavsky, Gennady	110 Surgery - Urology	A Multi-Center, Randomized, Assessor-Blind, Controlled Clinical Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH)
Bratslavsky, Gennady	110 Surgery - Urology	Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study
Bratslavsky, Gennady	110 Surgery - Urology	A Phase III, Multicenter, Randomized, Placebo- Controlled, Double-Blind Study of Atezolizumab (ANTI-PD-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
Bratslavsky, Gennady	110 Surgery - Urology	A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Jacob, Joseph M.	110 Surgery - Urology	Phase 3 Open Label multi center evaluating efficacy & safety of TAR-200 with Cetrelimab
Jacob, Joseph M.	110 Surgery - Urology	uTRACT Jelmyto Registry
Jacob, Joseph M.	110 Surgery - Urology	A phase 2 open label multi centr randomized study of TAR-200 in combination with cetrelimab and cetrelimab alone in participants with muscle invasive urothelial carcinoma of the bladder who are scheduled for radical cystectomy and are ineli
Jacob, Joseph M.	110 Surgery - Urology	A phase 2 single arm study of CG0070 combined with pembrolizumab in patients with non muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette guerin (BCG)
Jacob, Joseph M.	110 Surgery - Urology	Phase 2b clincial study evaluating effacacy and safety of TAR-200 in combination with cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high risk nonmuscle invasive bladder cancer (NMIBC) unresponsive to intravescial bacil
Kotula, Leszek	110 Surgery - Urology	Defining the ABI1-mediated resistance to enzalutamide
Kotula, Leszek	110 Surgery - Urology	Developing novel approaches to target ABI1 metastatic gene signature toward breast cancer care
Kotula, Leszek	110 Surgery - Urology	Prostate cancer and treatment induced dementia
Mollapour, Mehdi	110 Surgery - Urology	Regulatory mechanisms of the Hsp90 chaperone machinery



The Office of Research for Medical Students PRINCIPAL INVESTIGATOR	DEPARTMENT/DIVISION	PROJECT TITLE
Mollapour, Mehdi	110 Surgery - Urology	Targeting the serine/threonine-protein phosphatase-5 in kidney cancer
Mollapour, Mehdi	110 Surgery - Urology	PP5 as a biomarker for tumor development and progression
Nikolavsky, Dmitriy	110 Surgery - Urology	Controlling catheter associated urinary tract infections using smart catheters with rationally designed active topographies
Wiener, Scott V.	110 Surgery - Urology	Evaluation of Applaud Medical's Acoustic Enhancer with laser lithotripsy system in the treatment of urinary stones